Central nervous system serotonin: From neurobiology and genetics towards pharmacology, psychiatry and neurology;A szerotonin a központi idegrendszerben: Kirándulás a neurobiológiától, genetikától a farmakológia, pszichiátria és neurológia felé

Orvoskepzes

Volumn 84, Issue SUPPL. 2, 2009, Pages 73-92

  György, Bagdy ^a   János, Filakovszky ^a   Sándor, Kántor ^a   Gabriella, Juhász ^a   Márton, Graf ^a   Rita, Jakus ^a   Xénia, Gonda ^a   Terézia, Zsombók ^a   Csaba, Ádori ^a   Brigitta, Balogh ^a   Eszter, Kirilly ^a   Dénes, Andó Rómeó ^a   Judit, Lazáry ^a   Norbert, Gyöngyösi ^a   Anita, Benko ^a   Eszter, Molnár ^a   Tamás, Kitka ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

5 HT receptors; Anxiety; Cellular signals; CGRP; Depression; Drug therapy; Ecstasy; Epilepsy; Gene environment interaction; Genetic polymorphism; MDMA; Migraine; Neuronal damage; Serotonin (5 HT); Serotonintransporter; Sleep

Indexed keywords

EID: 82955251658     PISSN: 00306037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Filakovszky J. A tüske-hullám minta elofordulá sára ható tényezok vizsgálata klinikai és kísérleti körülmények között. Az 5-HT és glutamát neurotranszmisszió, és a vigilancia szerepe a tüske-hullám minta elofordulásában. Budapest: Semmelweis Egyetem: 2001.
2. Kantor S. A szerotonin-2 (5-HT2) receptorok szerepe a szorongás és az alvás szabályozásában. Budapest: Semmelweis Egyetem; 2002.
3. Juhasz G. A szerotonin és a CGRP szerepe a migrénben: genetikai és neurokémiai vizsgálatok. Budapest: Semmelweis Egyetem; 2003.
4. Graf M A szelektív szerotonin felvétel gátló antidepresszánsok hatása egyes szerotonin receptor altípusok muködésére patkányban. Budapest: Semmelweis Egyetem; 2005.
5. Jakus R. A tüskehullám-mintát befolyá soló neurotranszmitterek vizsgálata absence epilepsziában: A szerotonin, a glutamát és a glicin szerepe a tüskehullám-minta kialakulásában. Budapest: Semmelweis Egyetem; 2005.
6. Gonda X. A szerotonin transzporter gén és a személyiség: az 5HTTLPR s alléi, a szorongás, a depresszió és az affektív temperamentumok összefüggése Budapest: Semmelweis Egyetem; 2007.
7. Zsombok T. Szervformulával és mozgásterá piás elemekkel kombinált autogén tréning hatása a spontán és provokált migrénes fejfájásra. Budapest: Semmelweis Egyetem; 2007.
8. Balogh B. Az MDMA hatásai a vigilanciára és neuronkárositó hatásának farmakológiai következményei. Budapest: Semmelweis Egyetem; 2008.
9. Adori C. Ubiqutin-proteaszóma rendszer komponenesek és a HSP72 lokalizációja kontroll és neurodegenerativ agyszövetben. Budapest: EL TE TTK Biológia Doktori Iskola; 2007.
10. Baumgarten H, Göthert M. Serotonergic Neurons and 5-HT receptors in the CNS. Berlin: Springer; 2000.
11. Murphy D, Mueller E, Aulakh C, Bagdy G, Garrick W. Serotonin function in neuropsychiatric disorders. In: Mylecharane EJ dl LI, Augus JA, Humphrey PPA, editor. Serotonin. London: Macmillan Press; 1989. p. 257-64.
12. Palkovits M. Anatomy of neural pathways affecting CRH secretion. Ann N Y Acad Sci. 1987;512:139-48.
13. Lerer B. Pharmacogenetics of Psychotrophic drugs. Cambridge: Cambridge University Press; 2002.
14. Hoffman BJ, Hansson SR, Mezey E, Palkovits M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinal. 1998 Jul; 19(3):187-231. (Pubitemid 28347696)
15. Alexander SP, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol. 2008 Mar; 153 Suppl 2:S1-209.
16. Millan MJ, Marin P, Bockaert J, La Cour CM. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci. 2008 Sep; 29(9):454-64.
17. Walling KJ. The Sigma-RBl Handbook of Receptor Classification and Signal Transduction. Fourth Edition ed. Natick, MA: Sigma-RBl; 2001.
18. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999 Aug; 38(8):1083-152. (Pubitemid 29292403)
19. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994 Jun; 46(2):157-203. (Pubitemid 24185150)
20. Sanger GJ. 5-Hydroxytryptamine and the gastrointestinal tract: where next? Trends Pharmacol Sci. 2008 Aug. 11; 29:472-92.
21. Bagdy G, Calogero AE, Murphy DL, Szemeredi K. Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats. Endocrinology. 1989 Nov; 125(5):2664-9. (Pubitemid 19279458)
22. Bagdy G, Makara GB. Hypothalamic paraventricular nucleus lesions differentially affect serotonin-1A (5-HT1A) and 5-HT2 receptor agonist-induced oxytocin, prolactin, and corticosterone responses. Endocrinology. 1994 Mar; 134(3):1127-31.
23. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry. 1991 Dec. 1; 30(11):1139-66.
24. Bagdy G, Szemeredi K, Kanyicska B, Murphy DL. Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. J Pharmacol Exp Ther. 1989 Jul; 250(1):72-8. (Pubitemid 19194975)
25. Bagdy G. Serotonin, anxiety, and stress hormones. Focus on 5-HT receptor subtypes, species and gender differences. Ann N Y Acad Sci. 1998 Jun. 30; 851:357-63.
26. Ramage AG, Villalon CM. 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci. 2008 Aug. 22; 29:465-72.
27. Gaszner P, Faludi G, Kovács G, Molnár G, Kerpel-Frónius S, Bagdy G, et al. Pszichofarmakonok protokollja MOTESZ Magazin. 2003 Suppl. (2):1-18.
28. Kitka T, Bagdy G. Effect of 5-HT2AJ2B/2C receptor agonists and antagonists on sleep and waking in laboratory animals and humans. In: Monti JM P-PS, Jacobs BL, Nutt DJ, editor. Serotonin and Sleep: Molecular, Functional and Clinical Aspects Basel: Birkhauser Verlag; 2008.
29. Juhasz G, Zsombok T, Gonda X, Nagyne N, Modosne E, Bagdy G. Effects of autogenic training on nitroglycerin-induced headaches. Headache. 2007 Mar; 47(3):371-83. (Pubitemid 46426413)
30. Juhasz G, Zsombok T, Módos EA, Olajos S, Jakab B, Nemeth J, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003 Dec; 106(3). 461-70. (Pubitemid 37505895)
31. Juhasz G, Zsombok T, Gonda X, Bagdy G. A nitroglicerin által okozott fejfájások. Orvosi Hetilap. 2004;145:2323-8.
32. Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005 Mar; 25(3):179-83. (Pubitemid 40321709)
33. 2A receptor gene 102T/C polymorphism and migraine. J Neurogenet. 2003 Apr-Sep;17(2-3):231-40. (Pubitemid 38055575)
34. Juhasz G, Zsombok T, Laszik A, Jakus R, Faludi G, Sotonyi P, et al. Despite the general correlation of the serotonin transporter gene regulatory region polymorphism (5-HTTLPR) and platelet serotonin concentration, lower platelet serotonin concentration in migraine patients is independent of the 5-HTTLPR variants. Neurosci Lett. 2003 Oct. 16; 350(1):56-60. (Pubitemid 37289253)
35. Zsombok T, Juhasz G, Budavari A, Vitrai J, Bagdy G. Effect of autogenic training on drug consumption in patients with primary headache: an 8-month follow-up study. Headache. 2003 Mar; 43(3):251-7. (Pubitemid 36348772)
36. Filakovszky J, Gerber K, Bagdy G. A serotonin-1A receptor agonist and an N-methyl-D-aspartate receptor antagonist oppose each others effects in a genetic rat epilepsy model. Neurosci Lett. 1999 Feb. 12;261(1-2):89-92. (Pubitemid 29100083)
37. Filakovszky J, Kantor S, Halasz P, Bagdy G. 8-OH-DPAT and MK-801 affect epileptic activity independently of vigilance. Neurochem Int. 2001 Jun; 38(7):551-6. (Pubitemid 32268619)
38. Gerber K, Filakovszky J, Halasz P, Bagdy G. The 5-HT IA agonist 8-OH-DPA T increases the number of spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res. 1998 Oct. 5;807(1-2):243-5. (Pubitemid 29005263)
39. Graf M, Jakus R, Kantor S, Levay G, Bagdy G. Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy. Neurosci Lett. 2004 Apr. 8;359(1-2):45-8. (Pubitemid 38446635)
40. Jakus R, Graf M, Juhasz G, Gerber K, Levay G, Halasz P, et al. 5-HT2C receptors inhibit and 5-HT1A receptors activate the generation of spike-wave discharges in a genetic rat model of absence epilepsy. Exp Neurol. 2003 Dec; 184(2). 964-72. (Pubitemid 38182825)
41. Bagdy G, Kecskemeti V, Riba P, Jakus R. Serotonin and epilepsy. J Neurochem. 2007 Feb; 100(4):857-73. (Pubitemid 46213913)
42. Jakus R, Graf M, Ando RD, Balogh B, Gacsalyi I, Levay G, et al. Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res. 2004 May 22; 1008(2):236-44. (Pubitemid 38624054)
43. Bagdy G. Role of the hypothalamic paraventricular nucleus in 5-HTIA, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. Behav Brain Res. 1996;73(1-2):277-80.
44. Bagdy G, Calogero AE, Szemeredi K, Gomez MT, Murphy DL, Chrousos GP, et al. Beta-endorphin responses to different serotonin agonists: in volvement of corticotropin-releasing hormone, vasopressin and direct pituitary action. Brain Res. 1990 Dec. 24; 537 (1-2). 227-32.
45. Bagdy G, Kalogeras KT, Szemeredi K. Effect of 5-HT1C and 5-HT2 receptor stimulation on excessive grooming, penile erection and plasma oxytocin concentrations. Eur J Pharmacol. 1992 Dec. 8; 229(1):9-14.
46. Bagdy G, Makara GB. Paraventricular nucleus controls 5-HT2C receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses. Eur J Pharmacol. 1995 Mar. 14; 275(3):301-5.
47. Bagdy G, Sved AF, Murphy DL, Szemeredi K. Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. Eur J Pharmacol. 1992 Jan 21; 210(3):285-9.
48. Arato M, Bagdy G. Gender difference in m-CPP challenge test in healthy volunteers. Int J Neuropsychopharmacol. 1998 Dec; 1(2):121-4. (Pubitemid 128538372)
49. Bagdy G, Aroto M. Gender-dependent dissociation between oxytocin but not A CTH, Cortisol or TSH responses to m-chlorophenylpiperazine in healthy subjects. Psychopharmacology (Berl). 1998 Apr; 136(4):342-8. (Pubitemid 28189663)
50. Graf M, Kantor S, Anheuer ZE, Modos EA, Bagdy G. m-CPP-induced self-grooming is mediated by 5-HT2C receptors. Behav Brain Res. 2003 Jun. 16; 142(1-2):175-9. (Pubitemid 36677604)
51. Kantor S, Graf M, Anheuer ZE, Bagdy G. Rapid desensitization of 5-HT (1A) receptors in Fawn-Hooded rats after chronic fluoxetine treatment. Eur Neuropsychopharmacol. 2001 Feb; 11(1). 15-24. (Pubitemid 32162498)
52. To CT, Anheuer ZE, Bagdy G. Effects of acute and chronic fluoxetine treatment of CRH-induced anxiety. Neuroreport. 1999 Feb. 25; 10(3):553-5. (Pubitemid 29333281)
53. To CT, Bagdy G. Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment. Neuropharmacology. 1999 Feb; 38(2):279-82. (Pubitemid 29073548)
54. Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol. 2001 Dec; 4(4):399-408. (Pubitemid 33151684)
55. Gonda X, Juhasz G, Laszik A, Rihmer Z, Bagdy G. Subthreshold depression is linked to the functional polymorphism of the 5HT transporter gene. J Affect Disord. 2005 Aug; 87(2-3):291-7. (Pubitemid 41039951)
56. Gonda X, Rihmer Z, Juhasz G, Zsombok T, Bagdy G. High anxiety and migraine are associated with the s allele of the 5HTTLPR gene polymorphism. Psychiatry Res. 2007 Jan 15;149(1-3):261-6. (Pubitemid 46108113)
57. Gonda X, Rihmer Z, Zsombok T, Bagdy G, Akiskai KK, Akiskai HS. The 5HTTLPR polymorphism of the serotonin transporter gene is associated with affective temperaments as measured by TEMPS-A. J Affect Disord. 2006 Apr; 91(2-3):125-31.
58. Lazary J, Lazary A, Gonda X, Benko A, Molnár E, Juhasz G, et al. New evidence for the association of the serotonin transporter gene (SLC6A4) haplotypes, threatening life events, and depressive phenotype. Biol Psychiatry. 2008 Sep. 15; 64(6):498-504.
59. Gyöngyösi N, Balogh B, Kirilly E, Kilka T, Kantor S, Bagdy G. MDMA treatment 6 months earlier attenuates the effects of CP-94, 253, a 5-HT1B receptor agonist, on motor control but not sleep inhibition. Brain Res. 2008 Sep. 22; 1231:34-46.
60. Kantor S, Jakus R, Balogh B, Benko A, Bagdy G. Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505. Br J Pharmacol. 2004 Aug; 142(8):1332-42. (Pubitemid 39178887)
61. Kantor S, Jakus R, Molnár E, Gyöngyösi N, Toth A, Detari L, et al. Despite similar anxiolytic potential, the 5-hydroxytryptamine 2C receptor antagonist SB-242084 [6-chloro-5-methyl-l-[2-(2-methylpyrid-3-yloxy)- pyrid-5-yl carbamoyl] indoline] and chlordiazepoxide produced differential effects on electroencephalogram power spectra. J Pharmacol Exp Ther. 2005 Nov; 315(2):921-30. (Pubitemid 41500759)
62. Kantor S, Jakus R, Bodizs R, Halasz P, Bagdy G. Acute and long-term effects of the 5-HT2 receptor antagonist ritanserin on EEG power spectra, motor activity, and sleep: changes at the light-dark phase shift. Brain Res. 2002 Jul. 5; 943(1):105-11. (Pubitemid 34671178)
63. Bagdy G. Amit az ecstasyról tudni kell. Budapest: Akadémia Kiadó; 2006.
64. Adori C, Ando RD, Kovács GG, Bagdy G. Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in Dark Agouti rat: temporal, spatial, and cellular patterns. J Comp Neurol. 2006 Jul. 10; 497(2) 251-69. (Pubitemid 43825430)
65. Kirilly E, Molnár E, Balogh B, Kantor S, Hansson SR. Palkovits M, et al. Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days. Int J Neuropsychopharmacol. 2008 Sep; 11(6):795-809.
66. Kovacs GG, Ando RD, Adori C, Kirilly E, Benedek A, Palkovits M, et al. Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord. Neuropathol Appl Neurobiol. 2007 Apr; 33(2):193-203. (Pubitemid 46385713)
67. Balogh B, Molnár E, Jakus R, Quate L, Olverman HJ, Kelly PA, et al. Effects of a single dose of 3, 4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA. Psychopharmacology (Berl). 2004 May; 173(3-4):296-309. (Pubitemid 38703803)
68. Ando RD, Benko A, Ferrington L, Kirilly E, Kelly PA, Bagdy G. Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test. Neuropharmacology. 2006 Jun; 50(7):884-96.
69. Kirilly E, Benko A, Ferrington L, Ando RD, Kelly PA, Bagdy G. Acute and long-term effects of a single dose of MDMA on aggression in Dark Agouti rats. Int J Neuropsychopharmacol. 2006 Feb; 9(1):63-76. (Pubitemid 43068335)